Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
Diverticular Disease of the Colon01:27

Diverticular Disease of the Colon

Diverticular disease involves the formation of diverticula—small sac-like outpouchings of the colonic wall—and their complications. It most commonly affects the sigmoid colon due to higher intraluminal pressure and structural vulnerability. It results from structural weakness and increased pressure in the colon, producing pseudodiverticula that may remain silent or progress to inflammation and serious complications.Structure of DiverticulaIn diverticulosis, these outpouchings are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond the bowel: three rare complications of upadacitinib therapy in inflammatory bowel disease.

Journal of Crohn's & colitis·2026
Same author

Spatial transcriptomics atlas of inflammatory bowel disease to guide implementation in research consortiums and clinical trials.

Nature communications·2026
Same author

Impact of Immunogenicity on Clinical Outcomes in Patients With Moderate-to-Severe Inflammatory Bowel Disease Receiving Subcutaneous Infliximab: A Post Hoc Analysis of the LIBERTY Trials.

United European gastroenterology journal·2026
Same author

Reply.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Recovery of response and long-term outcomes following loss of response and dose escalation of subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD & LIBERTY-UC trials.

Inflammatory bowel diseases·2026
Same author

Correlation between patient-determined inflammatory bowel disease severity and the inflammatory bowel disease severity index.

The New Zealand medical journal·2026

Related Experiment Video

Updated: Jul 14, 2026

Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch
08:51

Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch

Published on: August 24, 2019

Acute and chronic megacolon.

Stephen B Hanauer1, Arnold Wald

  • 1Arnold Wald, MD Section of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, H6/516 CSC, Madison, WI 53792-5124, USA. axw@medicine.wisc.edu.

Current Treatment Options in Gastroenterology
|June 6, 2007
PubMed
Summary

Differentiating toxic megacolon, Ogilvie's syndrome, and chronic megacolon is crucial for effective treatment. Management strategies vary, ranging from intensive medical and surgical care for toxic megacolon to supportive therapies and pharmacologic agents for Ogilvie's syndrome and surgical options for chronic megacolon.

More Related Videos

Murine Endoscopy for In Vivo Multimodal Imaging of Carcinogenesis and Assessment of Intestinal Wound Healing and Inflammation
09:42

Murine Endoscopy for In Vivo Multimodal Imaging of Carcinogenesis and Assessment of Intestinal Wound Healing and Inflammation

Published on: August 26, 2014

Murine Distal Colostomy, A Novel Model of Diversion Colitis in C57BL/6 Mice
08:20

Murine Distal Colostomy, A Novel Model of Diversion Colitis in C57BL/6 Mice

Published on: July 12, 2018

Related Experiment Videos

Last Updated: Jul 14, 2026

Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch
08:51

Murine Appendectomy Model of Chronic Colitis Associated Colorectal Cancer by Precise Localization of Caecal Patch

Published on: August 24, 2019

Murine Endoscopy for In Vivo Multimodal Imaging of Carcinogenesis and Assessment of Intestinal Wound Healing and Inflammation
09:42

Murine Endoscopy for In Vivo Multimodal Imaging of Carcinogenesis and Assessment of Intestinal Wound Healing and Inflammation

Published on: August 26, 2014

Murine Distal Colostomy, A Novel Model of Diversion Colitis in C57BL/6 Mice
08:20

Murine Distal Colostomy, A Novel Model of Diversion Colitis in C57BL/6 Mice

Published on: July 12, 2018

Area of Science:

  • Gastroenterology
  • Colorectal Surgery
  • Internal Medicine

Background:

  • Megacolon, characterized by colon dilation, presents acutely or chronically.
  • Acute forms include toxic megacolon (with inflammation) and Ogilvie's syndrome (without apparent colonic disease).
  • Distinguishing these conditions is vital due to differing pathophysiologies and management approaches.

Purpose of the Study:

  • To outline the distinct characteristics and management strategies for toxic megacolon, Ogilvie's syndrome, and chronic megacolon in adults.
  • To emphasize the critical importance of accurate diagnosis for appropriate patient care.

Main Methods:

  • Review of toxic megacolon management: resuscitation, corticosteroids, antibiotics, and surgical intervention criteria.
  • Overview of Ogilvie's syndrome treatment: supportive care, neostigmine, colonoscopic decompression, and polyethylene glycol solutions.
  • Description of chronic megacolon therapy: colon cleansing, impaction prevention, and surgical options for refractory cases.

Main Results:

  • Toxic megacolon necessitates immediate medical and surgical intervention, with surgery indicated for non-response or perforation.
  • Ogilvie's syndrome management focuses on preventing ischemia and perforation through supportive measures and pharmacologic/endoscopic decompression.
  • Chronic megacolon management aims to alleviate symptoms and prevent complications through bowel cleansing and, in severe cases, surgical resection.

Conclusions:

  • Accurate differentiation of megacolon subtypes is essential for guiding treatment decisions.
  • Toxic megacolon is a medical emergency requiring prompt, aggressive management.
  • Ogilvie's syndrome and chronic megacolon have distinct management pathways, often involving less invasive or palliative approaches.